# 2025-08148: Voriconazole Test System Classified as Class II by FDA

2025-08148, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Voriconazole Test System, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08148
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08148
- Title: Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Voriconazole Test System
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19625
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

Voriconazole Test System Classified as Class II by FDA

## Summary

The FDA is officially classifying the voriconazole test system as a Class II device with special safety rules, making it safer and easier to get to patients. This change lowers regulatory hurdles, speeding up access to this important medical test without extra costs. The new classification is effective May 9, 2025, benefiting device makers and patients alike.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the voriconazole test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the voriconazole test system's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Voriconazole Test Moved to Class II: benefit, medium. The FDA has classified the voriconazole test system as Class II (special controls) effective May 9, 2025 (classification was applicable May 5, 2017). FDA states this classification will reduce regulatory burdens and enhance patients' access to the test by placing it in a lower device class than the…
- Enables Use as Predicate for 510(k) Devices: benefit, medium. By classifying the device into Class II via the De Novo process, the voriconazole test system can serve as a predicate device that other sponsors may rely on to submit less-burdensome 510(k) premarket notifications rather than De Novo or premarket approval.
- Required Validation Studies and Study Details: cost, medium. Manufacturers must meet special controls including design verification and validation with: precision studies using a minimum of three samples at different concentrations (including near medical decision points), method comparison data collected at three laboratory sites with a comparator method no…
- Labeling Must Carry Specific Warning: benefit, low. The device labeling must include the warning statement: "This assay should only be used in conjunction with information available from clinical evaluations and other diagnostic procedures." This labeling requirement is part of the special controls for the voriconazole test system (21 CFR 862.3970(b…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08148 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08148/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classification-of-the)
- [2025-08148 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08148.pdf)

## Related
- [Previous: 2025-08147, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classifica…](https://policyrisk.com/federal-register/2025-08147)
- [Next: 2025-08149, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2025-08149)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08148 (as of 2026-10-16).
